Plaque Psoriasis

The FDA has charged Bausch Health with making false or misleading claims about its topical plaque psoriasis cream Duobrii.

BOSTON — Patients with moderate to severe plaque psoriasis experienced significant improvement after treatment with tildrakizumab in a real-world study, according to a poster presented at the American Academy of Dermatology Annual Meeting.

The Janssen Pharmaceutical Companies of Johnson & Johnson launched VISIBLE, a phase 3b study with a focus on plaque and scalp psoriasis in people of color, according to a press release.

BOSTON — Improvement in plaque psoriasis itch and severity, including in intertriginous areas, was significant in patients treated with roflumilast, according to a poster presented at the American Academy of Dermatology Annual Meeting.

Plaque psoriasis patients who had residual plaques following ixekizumab saw success with adjunctive calcipotriene 0.005%/betamethasone dipropionate 0.064% foam, according to a study.

The FDA has approved AbbVie’s risankizumab-rzaa for the treatment of adults with active psoriatic arthritis, expanding its initial indication from plaque psoriasis only.

Vunakizumab showed efficacy in treating moderate to severe plaque psoriasis at all dose levels, with a 240 mg dose showing the best clinical response, according to a phase 2 trial.

The FDA has approved Otezla for the treatment of patients with plaque psoriasis of all severity levels, according to a company press release.

Once-daily topical tapinarof cream reduced the severity of plaque psoriasis, as well as improved patient-reported outcomes, according to two phase 3 clinical trials.

The FDA has accepted a New Drug Application, while the European Medicines Agency validated a Marketing Authorization Application for deucravacitinib for the treatment of plaque psoriasis, Bristol Myers Squibb announced in a press release.